N@N

Debjit Chattopadhyay Maintained (BMRN) at Strong Buy with Decreased Target to $120 on, Apr 27th, 2023

^{Published on 2024-10-28 03:06:53 - WOPRAI, Debjit Chattopadhyay}
 

Debjit Chattopadhyay of Guggenheim, Maintained "BioMarin Pharmaceutical Inc." (BMRN) at Strong Buy with Decreased Target from $125 to $120 on, Apr 27th, 2023.

Debjit has made no other calls on BMRN in the last 4 months.

There are 7 other peers that have a rating on BMRN. Out of the 7 peers that are also analyzing BMRN, 3 agree with Debjit's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Kostas Biliouris of "BMO Capital" Maintained at Hold with Decreased Target to $102 on, Tuesday, March 7th, 2023
• Whitney Ijem of "Canaccord Genuity" Maintained at Hold with Decreased Target to $112 on, Tuesday, February 28th, 2023
• Leland Gershell of "Oppenheimer" Downgraded from Buy to Hold on, Wednesday, February 22nd, 2023

These are the ratings of the 4 analyists that currently disagree with Debjit

---

• William Pickering of "Bernstein" Initiated at Sell and Held Target at $81 on, Tuesday, March 21st, 2023
• Matthew Harrison of "Morgan Stanley" Maintained at Buy with Decreased Target to $131 on, Tuesday, February 28th, 2023
• Paul Matteis of "Stifel" Maintained at Strong Buy with Increased Target to $118 on, Tuesday, February 28th, 2023
• Joseph Schwartz of "SVB Leerink" Maintained at Buy with Increased Target to $130 on, Friday, February 3rd, 2023

Contributing Sources

---